These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9382011)

  • 41. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities.
    Lewis GF; O'Meara NM; Soltys PA; Blackman JD; Iverius PH; Pugh WL; Getz GS; Polonsky KS
    J Clin Endocrinol Metab; 1991 Apr; 72(4):934-44. PubMed ID: 2005221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gender differences and diabetic status in the relationship of blood apolipoprotein C-III, free fatty acids and triglycerides in subjects at risk for glucose intolerance].
    Flórez H; Méndez AJ; Jones L; Goldberg RB
    Invest Clin; 1999 Mar; 40(1):51-66. PubMed ID: 10198561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
    Wolf P; Winhofer Y; Krssak M; Smajis S; Harreiter J; Kosi-Trebotic L; Fürnsinn C; Anderwald CH; Baumgartner-Parzer S; Trattnig S; Luger A; Krebs M
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):387-92. PubMed ID: 27118107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.
    Abbasi F; Carantoni M; Chen YD; Reaven GM
    Diabetes Care; 1998 Aug; 21(8):1301-5. PubMed ID: 9702437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity.
    Nielsen R; Nørrelund H; Kampmann U; Kim WY; Ringgaard S; Schär M; Møller N; Bøtker HE; Wiggers H
    Circ Heart Fail; 2013 Jul; 6(4):845-52. PubMed ID: 23733915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats.
    Kim YW; Kim JY; Lee SK
    J Korean Med Sci; 1995 Feb; 10(1):24-30. PubMed ID: 7598820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of insulin and acute diabetes on plasma FFA and ketone bodies in the fasting rat.
    Bieberdorf FA; Chernick SS; Scow RO
    J Clin Invest; 1970 Sep; 49(9):1685-93. PubMed ID: 5452413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients.
    Riemens SC; van Tol A; Sluiter WJ; Dullaart RP
    Diabetes; 1999 Aug; 48(8):1631-7. PubMed ID: 10426383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.
    Rigazio S; Lehto HR; Tuunanen H; Någren K; Kankaanpaa M; Simi C; Borra R; Naum AG; Parkkola R; Knuuti J; Nuutila P; Iozzo P
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E413-9. PubMed ID: 18505832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control.
    Haugaard SB; Mu H; Vaag A; Madsbad S
    Eur J Endocrinol; 2009 Jul; 161(1):57-64. PubMed ID: 19417077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irregular circulating insulin concentrations in type 2 diabetes mellitus: an inverse relationship between circulating free fatty acid and the disorderliness of an insulin time series in diabetic and healthy individuals.
    Schmitz O; Juhl CB; Hollingdal M; Veldhuis JD; Pørksen N; Pincus SM
    Metabolism; 2001 Jan; 50(1):41-6. PubMed ID: 11172473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
    Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
    Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.
    Monti LD; Lucignani G; Landoni C; Moresco RM; Piatti P; Stefani I; Pozza G; Fazio F
    Diabetes; 1995 May; 44(5):537-42. PubMed ID: 7729612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.